The summer months typically lack big headlines in the stock market. But that hasn’t been the case this year…

On today’s new episode of the SteadyTrade Podcast, Tim Bohen and Matt McCall dissect some of the hottest stories of the last week and what they mean for your portfolio.

Finally, they begin sharing the names of six stocks at the top of their watch lists. All are small caps that will benefit from our thesis that smaller stocks will outperform their larger counterparts in the coming months…

Watch Here

Learn more about their favorite niche sectors here:
https://university.stockstotrade.com/wp-content/uploads/2024/07/Future-500-Stock-Report.pdf

It has been a few days since President Joe Biden’s announcement that he’s dropping out of the 2024 presidential election rocked the world. That has given us some time to think about the implications for the election, the stock market, and the future of our country.

On today’s new episode of the SteadyTrade Podcast, Tim Bohen and Matt share their views of the historic decision. And more importantly, we discuss what it all means for your investments.

They focus on what a potential second Trump presidency would look like and what sectors would be affected. From the positives for fossil fuels, cryptos, manufacturing, and small caps to the negatives for renewable energy, electric vehicles, and China-based stocks, this is a must-watch episode to prepare your portfolio for the 2024 election.

Watch Here

The healthcare industry as we know it today will be unrecognizable a decade from now…

Several technological breakthroughs are coming together to upend one of the largest industries in the world. And one of the biggest culprits is artificial intelligence (AI).

On today’s episode of the SteadyTrade Podcast, Tim Bohen and Matt McCall dive into some of the biggest implications that AI will have on the future of the healthcare industry.

It currently takes about 10 years and more than $1 billion to take a drug from the discovery phase to full FDA approval. That is incredibly costly and timely. But what makes the process even worse is that only about one in 10 potential drugs make it all the way through that cycle.

Think about all the data that’s created throughout the drug discovery process…

That makes it the perfect niche sector to be disrupted by the power of AI.

On the podcast, Tim and Matt share their big-picture thoughts regarding where we are in the AI-drug discovery stocks cycle and where the opportunities lie today. Several small companies are working to meld AI with the current drug-discovery process, and you can be sure they give you a few names to add to your watch list.

Watch Here!